The PD-L1/PD-1 pathway is a critical component of the immunosuppressive tumor microenvironment in acute myeloid leukemia (AML), but little is known about its regulation. We investigated the role of the MUC1 oncoprotein in modulating PD-L1 expression in AML. Silencing of MUC1 in AML cell lines suppressed PD-L1 expression without a decrease in PD-L1 mRNA levels, suggesting a posttranscriptional mechanism of regulation. We identified the microRNAs miR-200c and miR-34a as key regulators of PD-L1 expression in AML. Silencing of MUC1 in AML cells led to a marked increase in miR-200c and miR-34a levels, without changes in precursor microRNA, suggesting that MUC1 might regulate microRNA-processing. MUC1 signaling decreased the expression of the microRNAprocessing protein DICER, via the suppression of c-Jun activity. NanoString (Seattle, WA, USA) array of MUC1-silenced AML cells demonstrated an increase in the majority of probed microRNAs. In an immunocompetent murine AML model, targeting of MUC1 led to a significant increase in leukemia-specific T cells. In concert, targeting MUC1 signaling in human AML cells resulted in enhanced sensitivity to T-cell-mediated lysis. These findings suggest MUC1 is a critical regulator of PD-L1 expression via its effects on microRNA levels and represents a potential therapeutic target to enhance anti-tumor immunity.
INTRODUCTION
Acute myeloid leukemia (AML) is a lethal hematological malignancy in which the tumor microenvironment is characterized by an immunosuppressive milieu that fosters disease progression. 1, 2 The PD-L1/PD-1 pathway confers a critical negative co-stimulatory signal that induces T-cell exhaustion and supports immune evasion by malignant cells. [3] [4] [5] [6] In contrast, antibody blockade of PD-L1/PD-1 signaling results in the reversal of tumor-mediated immune suppression and durable responses in subsets of patients with solid tumors [7] [8] [9] and hematological malignancies. 10 Although PD-L1 expression in AML is dynamic, little is known about the mechanism(s) responsible for regulating PD-L1 expression in AML.
MUC1 is a heterodimeric oncoprotein aberrantly expressed in solid tumors and hematological malignancies including AML, that supports critical aspects of the malignant phenotype including cell proliferation, self-renewal and resistance to apoptosis. [11] [12] [13] [14] [15] [16] MUC1 interacts with the WNT/-catenin pathway and promotes the activation of WNT target genes, 17, 18 NFΚ-B [19] [20] [21] and STAT1/3, 22, 23 pathways critical for the proliferation and survival of tumor cells. In addition, MUC1 regulates pathways responsible for autonomous self-renewal 24 and is uniquely expressed on leukemia stem cells as compared to normal hematopoietic stem cells. 25 Inhibition of MUC1 using a cell-penetrating peptide (GO-203) that blocks MUC1-C homodimerization necessary for downstream signaling, 26, 27 abrogates leukemia engraftment and eradicates established disease in a xenogeneic leukemia model. 25 Given the critical function of MUC1, in supporting the malignant phenotype of AML blasts and stem cells, we sought to explore the role of MUC1 in mediating the immunosuppressive milieu of the tumor microenvironment. Here, we demonstrate that silencing of MUC1 markedly suppresses PD-L1 expression in AML cells. However, MUC1 suppression is associated with a paradoxical increase in PD-L1 mRNA, suggesting that MUC1 regulation of PD-L1 expression in AML occurs at the post-transcriptional level.
Noncoding RNAs epigenetically regulate critical aspects of the oncogenic phenotype through the disruption of protein translation via selective binding and degradation of target mRNAs. 28 The microRNAs miR-200c and miR-34a demonstrate homology with the 3′-UTR section of PD-L1 mRNA. 4, 29 was recently shown to downregulate the expression of PD-L1 protein in a lung cancer model, 29 and miR-34a was shown to target PD-L1 in AML cell lines. 4 In the present study, we demonstrate that MUC1 negatively regulates expression of miR-200c and miR-34a, which in turn controls PD-L1 expression in AML cells. Consistent with these findings, upregulation of miR-200c or miR-34a via lentiviral transduction results in a corresponding decrease in PD-L1 expression. Of note, silencing of MUC1 results in increased levels of mature miR-34a and miR-200c while precursor-microRNAs are unaffected. Consistent with this observation, MUC1 inhibition resulted in increased expression of DICER protein, which mediates the final splicing of precursor miRNAs to their active form. Indeed, microRNA array of MUC1-silenced AML cells demonstrated a profound global upregulation of microRNAs, consistent with an increase in DICER expression. These findings strongly suggest MUC1 as a key regulator of microRNA expression and demonstrate a critical mechanism by which MUC1 signaling exploits noncoding RNAs to elicit an immunosuppressive milieu in the bone marrow microenvironment (BM).
MATERIALS AND METHODS

Cell culture
The AML cells lines THP-1 and MOLM-14 and the murine cell line TIB-49 were purchased from ATCC, cultured at 37°C in a humidified 5% CO 2 incubator and maintained in RPMI 1640 media (Cellgro, Manassas, VA, USA) supplemented with heat-inactivated 10% human serum albumin (Sigma, St Louis, MO, USA) and 100 IU/ml penicillin, 100 μg/ml streptomycin (Cellgro). Cell lines were stably transduced with a lentiviral vector expressing a scrambled control shRNA (CshRNA, Sigma) or MUC1 shRNA (Sigma) in the presence of 4-8 g/ml polybrene (Sigma). Transduced cells were then selected using 2 ug/ml puromycin. For the CRISPR-edited cell line, sgRNAs targeting the first exon of the MUC1 gene were cloned into a lenti-plasmid (Genome Engineering Production Group, Harvard Medical School). MOLM-14 cells were transduced with viral vector containing the lenti-CRISPR plasmid and successfully transduced clones were selected for by limiting dilution and maintained in 2 μg/ml puromycin (Sigma). Alternatively, cells were stably transduced with lentiviral vectors expressing pHR-GFP, miR-200c or miR-34a with a GFP selection marker. Transduced cells were selected by flow cytometric sorting for GFP-positive cells. In a subset of experiments, tumor cells were obtained from BM aspirates or peripheral blood isolated from patients with AML at diagnosis. Patient characteristics are shown in Supplementary Table S1 . AML cells were treated once daily with 2.5 μM MUC1-C inhibitor peptide (GO-203) or a control peptide (CP-3) (AnaSpec) for 3 days. The culture medium was not supplemented with additional cytokines. In specific experiments, AML cells were treated for 30 min with 100 or 400 μM of c-Jun peptide inhibitor (Tocris, Bristol, UK) or control (phosphate-buffered saline).
In vivo model C57BL/6J mice were challenged with 100 × 10 3 GFP-transduced MUC1-Csilenced TIB-49 syngeneic AML cells via retro-orbital injection. TIB-49 cells underwent lentiviral transduction with shRNA hairpin against MUC1-C or a control shRNA. BM and spleen cells were isolated on day 14 and assessed for PD-L1 expression by multichannel flow cytometric analysis staining for GFP+ AML cells and PD-L1 expression using mouse antigen-presenting cell (APC) -conjugated anti-PD-L1 antibody. Alternatively, MUC1 signaling was inhibited via daily subcutaneous injection of the MUC1 inhibitor, GO-203, (14 mg/kg) initiated 24 h after tumor challenge.
AML-specific T cells were quantified in BM and spleen by flow cytometric analysis for intracellular IFN-γ expression following exposure to TIB-49 AML lysate. C57BL/6 mice were inoculated with 100 × 10 3 GFP-transduced syngeneic TIB-49 AML cells using retro-orbital injections. On day 14 following the inoculation BM cells were harvested and stimulated ex vivo with TIB-49 tumor lysate. Following 6 days of stimulation, CD4+ and CD8+ T cells underwent flow cytometric analysis for intracellular IFN-γ expression.
CTL assay
Lysis of AML cells by allogeneic T cells following MUC1 downregulation was assessed in a standard CTL flourochrome assay (OncoImmunin Inc., Gaithersburg, MD, USA). Target cells were incubated in APC labeled phosphate-buffered saline (1 μl of reconstituted TFL4 in phosphatebuffered saline at 1:3000 ratio) at 1 × 10 6 cells/ml for 30 min at 37°C. Labeled cells were washed twice in phosphate-buffered saline. Using MUC1-silenced or control MOLM-14 cell lines, healthy donor peripheral blood mononuclear cells (PBMCs) were co-incubated with labeled target cells in the presence of a fluorogenic granzyme B substrate for 1-2 h at 37°C. Cells were washed and analyzed by flow cytometry. Dead target cells are identified by cells that dually stain for granzyme B and APC label (right upper quadrant). As a negative control, Granzyme B positive tumor cells not co-cultured with T cells, were quantified.
The impact of MUC1 inhibition on CTL mediated killing of patientderived AML cells, by T cells stimulated with a dendritic cells (DCs)/AML fusion vaccine was examined. DC/AML fusions were generated as previously described. 30 Briefly, autologous DCs were generated by culture of adherent peripheral mononuclear cells obtained from AML patients following remission, in the presence of GM-CSF, IL-4 and TNF-α. DCs were fused with autologous AML blasts, obtained at diagnosis, by coculture at a 1:1 ratio in the presence of polyethylene glycol. Autologous T cells were then stimulated with the DC/AML fusion vaccine for 6 days. Subsequently, vaccine stimulated T cells were co-cultured with control autologous AML blasts or AML blasts exposed to daily treatment with 2.5 μM GO-203 for 3 days. The lysis of AML blasts, with and without treatment with GO-203, by vaccine stimulated T cells was detected using a standard CTL assay as described above.
FACS analysis
Cells were analyzed for PD-L1 expression by multichannel flow cytometric analysis. Cells were first incubated with FcR blocking reagent (Miltenyi, Bergisch Gladbach, Germany) for 10 min at room temperature. Subsequently, cells incubated with monoclonal antibody (MAb) anti-PD-L1-APC (Biolegend, San Diego, CA, USA), anti-CD38-PE or anti-CD117-PE (BD Pharmigen, San Jose, CA, USA) or the appropriate isotype control. The cells were then analyzed by flow cytometry using FACS Aria (BD Biosciences, San Jose, CA, USA). Analysis of the obtained data were performed using Kaluza software (Beckman Coulter, Brea, CA, USA).
The expression of IFN-γ was analyzed by intracellular flow cytometry. T cells were pulsed with GolgiStop (1 μg/ml; BD Pharmingen) for 4-6 h at 37°C before analysis. Cells were next harvested and labeled with CD4-PB and CD8-FITC. Cells were then permeabilized by incubation in Cyto-fix/Cytoperm plus (BD Pharmingen) containing formaldehyde and saponin for 30 min at 4°C, washed twice in Perm/Wash solution (BD Pharmingen), and incubated with PE-conjugated IFN-γ (Invitrogen, Camarillo, CA, USA), or a matched isotype control antibody for 30 min. Cells were washed in 1 × Perm/Wash solution and fixed in 2% paraformaldehyde (Sigma, St Louis, MO, USA) becasue of the analysis. For Ki-67 analysis, AML cells were permeabilized by incubation in Cyto-fix/Cytoperm plus (BD Pharmingen) as described above and incubated with PE-conjugated Ki-67 (BD Pharmingen). Ki-67 expression was then assessed using flow cytometry.
Luciferase activity of 3′-UTR PD-L1
The full length of human PD-L1 3′-UTR was cloned into the Psicheck2 vector (Promega, Madison, WI, USA). MOLM-14 AML cells were transduced with GFP control vector, miR-34a and miR-200c. GFP expressing cells were subsequently isolated used flow cytometric sorting. 200 × 10 3 viable cells from each cell line were transiently transfected with the luciferase reporter Psicheck2 vector 3′-UTR PD-L1, to test the capacity of miR-34a and miR-200c to bind the 3′-UTR of PD-L1 and suppress the luciferase activity of the reporter. Each cell line was seeded in triplicates and transfected with DharmaFECT Duo transfection agent (Dharmacon, Lafayatte, CO, USA). Twenty-four hours post transfection, the samples were lysed according to the instructions of Dual luciferase Reporter Assay System (Promega). Firefly and renilla luciferase activity were measured with GloMax luminometer (Promega).
Immunoblotting
Whole-cell lysates were prepared in RIPA lysis buffer and analyzed by immunoblotting with anti-MUC1-C (Thermo Scientific, Waltham, MA, USA,) anti-DICER, anti-Argo-2, anti-p-c-Jun, anti-c-Jun (Cell Signaling, Danvers, MA, USA) anti-PD-L1 (Abcam, Cambridge, MA, USA), anti-JNK, antiphospho-JNK, anti-ERK, anti-phospho-ERK, anti-GAPDH and anti-β-actin (Cell Signaling, Danvers, MA, USA) as described. 31 Immune complexes were detected using horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (GE Healthcare, Little Chalfont, UK).
Quantitative RT-PCR Total RNA was isolated from cells using the RNeasy total RNA isolation kit (Qiagen, Hilden, Germany). cDNA synthesis was performed with 1 μg of total RNA using the MiScript RT-PCR system (Qiagen). The SYBR green quantitative PCR (qPCR) assay kit (Roche, Basel, Switzerland) was used with 2 μl of diluted cDNA for each sample. The forward and reverse primers for qPCR of murine MUC1, human PD-L1, DICER, c-Jun, miR-200c, miR-34a, premir-200c, pre-mir-34a and GAPDH are listed in Supplementary Table S2 . Statistical significant was determined by the student's t-test.
Chromatin immunoprecipitations (ChIP)
THP-1 cells were crosslinked for 10 min in 1% formaldehyde at room temperature, followed by 0.125 M final concentration of glycine to stop fixation. Aliquots containing 1 × 10 6 nuclear equivalents were subjected to chromatin immunoprecipitation-PCR for c-Jun and IgG as described previously. 32 Crosslinked pellets were lysed for 10 min on ice and chromatin fragmented using a Branson 250 digital sonifier machine with 0.7 s 'On' and 1.3 s 'Off' pulses at 40% power amplitude for 2 × 2 min cycles. Solubilized chromatin was diluted and incubated with 1 μg antibody overnight at 4°C. Immune complexes were captured with a 50/50 slurry of protein A and protein G Dynabeads and enriched chromatin was isolated by reverse-crosslinking and proteinase K digestion at 65°C. AMPure XP beads (Beckman Coulter A63882) were used to clean up and isolate chromatin immunoprecipitation DNA for subsequent qPCR per manufactures protocol. The following antibodies were used for chromatin immunoprecipitation: c-Jun (Cell Signaling Technologies #9165) and IgG (Cell Signaling Technologies #2729). Binding sites for c-Jun in the DICER1 promoter were predicted using UCSC Genome browser 33 and three sets of primers (DICER1, 2 and 3) were manufactured using ThermoFischer custom Oligo design. C-Jun is a described auto-regulator of c-Jun 34 and was therefore used as a positive control. Primers are listed in Supplementary  Table S2 . The average Ct-value was determined from triplicate reactions and normalized against nonspecific IgG controls with standard curves for each primer pair.
mRNA Array RNA was isolated from paired GO-203 treated or control peptide-treated AML samples from three subjects (2.5 μM GO-203 daily for 3 days). Affymetrix (Santa Clara, CA, USA) mRNA expression array, consisting of 47 321 probe features corresponding to 34 692 transcripts, was performed as described 35 and all arrays were included in the differential expression analysis. Standard normalization methods were applied, followed by paired t-test analysis for Bonferroni-corrected significance, using the Limma Bioconductor package. Correction for multiple comparisons was performed using the false discovery rate of Benjamini and Hochberg. 36 miRNA Array RNA was isolated from AML cells as described and run in triplicate on a NanoString nCounter instrument using the human miRNA Expression Assay Kit v3, according to the manufacturer's instructions. Data obtained were then normalized to positive miRNA-ligation reaction controls and background noise was subtracted. Correction for multiple comparisons was performed using the false discovery rate of Benjamini and Hochberg. 36 Viability assays AML cells were seeded in white flat-bottom 96-well plates at 200 000 cells/ well. At 72 h of daily treatment with GO-203, cell viability was assessed using the CellTiter-Glo (CTG) Luminescent Cell Viability Assay. Raw luminescence values were obtained from each well using Infinite M200 Pro luminometer (Tecan, Mannedorf, Switzerland). Figures 1A and B) .
RESULTS
MUC1 inhibition leads to decrease in PD-L1 expression
To evaluate PD-L1 mRNA levels, MUC1 gene was silenced in MOLM-14 cells using CRISPR/Cas9 technology, and using MUC1-specific shRNA in THP-1 cells. Interestingly, increased levels of PD-L1 mRNA was observed in MUC1-silenced AML cells as determined by qPCR analysis (Figure 1d ), suggesting that MUC1 regulation of PD-L1 expression was accomplished via a post-transcriptional mechanism.
MiR-34a and miR-200c regulate PD-L1 expression in AML cells We hypothesized that MUC1 regulation of PD-L1 may be mediated by noncoding RNAs, which are known to epigenetically regulate cellular function via the binding and degradation of mRNAs with homologous sequences, providing a critical brake for protein translation. Consistent with this hypothesis, the PD-L1 3′-UTR contains multiple binding motifs for miR-200c 29 and one for miR-34a 4 (g) Subsequently, relative levels of miR-34a and miR200c were detected in these cells compared to controls using qPCR. Three patients were evaluated, the bar graphs represent patients AML2 and AML3 (Po0.05).
MUC1 inhibition leads to increase in DICER expression via c-Jun
We then sought to determine the mechanism by which MUC1 signaling negatively regulates expression of miR-34a and miR--200c, as these microRNAs represent a diverse species of noncoding RNAs that do not share a common promoter region.
We first examined the effect of MUC1 silencing on microRNAprocessing. MUC1-silenced MOLM-14 and THP-1 cells were analyzed for precursor miR-34a and miR-200c, to determine if MUC1 signaling effects miR-34a and miR-200c maturation to their functional conformation. The results demonstrated that silencing of MUC1 did not result in alteration of levels of the precursor miRNAs pre-mir-34a (Figure 3a) or pre-mir-200c (Figure 3b) , suggesting the regulatory effect of MUC1 on these microRNAs occurs at the post-transcriptional stage.
We subsequently investigated whether MUC1 signaling impacted the expression of DICER, an RNAase III that forms a critical component of the RNA-induced silencing complex, required for the generation of functionally competent microRNAs. We demonstrated the novel finding that the MUC1 oncoprotein regulates DICER expression impacting activation of noncoding RNAs in a class wide effect. MUC1 silencing resulted in increased expression of DICER protein in the MOLM-14 and THP-1 AML cell lines (Figure 3c) . Similarly, expression of DICER was increased following exposure of AML cells to the MUC1 inhibitor, GO-203. Of note, there was no change in the expression of the Argonaut 2 (Ago 2) protein, the 'catalytic engine' of the RNA-induced silencing complex (Figure 3d) . Interestingly, MUC1 silencing of both MOLM-14 and THP-1 cells lines resulted in the dramatic increase in DICER mRNA levels by qPCR analysis (Figure 3e) , consistent with regulation at the transcriptional level.
c-Jun, a member of the AP-1 transcription factor family, is known to have a binding site in the DICER1 gene promoter 37 and has been shown to mediate DICER expression in Breast Cancer 38 and T-cell leukemia. 37 Immunoblots of MUC1-silenced AML cells demonstrated an increase in total and phosphorylated forms of c-Jun (Figure 4a , n = 2). Consistent with this finding, MUC1-silenced AML cell lines demonstrated increased levels of c-Jun mRNA by qPCR analysis (Figure 4b, n = 2) . Furthermore, c-Jun was one of only 10 genes that demonstrated significant differential expression in a microarray analysis of gene expression of three paired GO-203 or control peptide-treated AML patient-derived samples, with MUC1 inhibition resulting in a statistically significant increase in c-Jun mRNA levels (false discovery rate-adjusted P = 0.003; Figure 4c ). An increase in c-Jun mRNA levels following MUC1 inhibition using GO-203 in patient-derived AML cells was validated using qPCR as demonstrated in Supplementary  Figure 2B To examine the downstream effect of c-Jun signaling on PD-L1 expression, MOLM-14 and THP-1 AML cells were treated with c-Jun inhibitor, as described above. Importantly, c-Jun inhibition of MUC1-silenced MOLM-14 and THP-1 cells led to an upregulation Figure 3 . MUC1 inhibition leads to increase in DICER expression. MUC1 was silenced in MOLM-14 cells using CRISPR/Cas9 technology and in THP-1 cells using transduction with MUC1-specific shRNA. Relative levels of (a) precursor mir-34a and (b) precursor mir-200c were detected using qPCR in MOLM-14 and THP-1 cells with silenced MUC1 levels compared to control cells (n = 2). (c) DICER and Ago-2 levels were assessed using western blot analysis in control and MUC1-silenced MOLM-14 and THP-1 cells (n = 3). (d) MOLM-14 and THP-1 cells were treated with 2 μM GO-203 or control peptide daily for 3 days. DICER and Ago-2 levels were detected using western blot analysis (n = 2). (e) DICER mRNA was detected using qPCR in MOLM-14 and THP-1 cells with silenced MUC1 levels compared to appropriate control cells (n = 2). To further investigate the mechanism by which MUC1 affects DICER expression, we evaluated potential mediators of MUC1 regulation of c-Jun. MUC1-silenced MOLM-14 and THP-1 cells were assessed for their expression of ERK and JNK; described mediators of c-Jun transcription [39] [40] [41] and phosphorylation, 42, 43 respectively. MUC1 silencing resulted in increased levels of total and phosphorylated ERK and JNK as demonstrated by immunoblot analysis (Figures 4g and h ; n = 2).
MUC1 inhibition leads to increase in microRNAs in AML cells
The finding that MUC1 regulates expression of DICER suggests that MUC1 exerts a class effect on the production of functionally mature miRNAs. To investigate this hypothesis, we performed an array to identify other microRNAs that were similarly impacted by silencing of MUC1. induction of PD-L1 expression in vivo. 6 To assess the effect of MUC1 silencing on PD-L1 expression in vivo, BM and spleen cells were isolated from mice, 14 days after inoculation. Gated GFP+ tumor cells were analyzed for PD-L1 expression using flow cytometric analysis. MUC1 silencing was shown to result in a statistically significant decrease in PD-L1 levels as demonstrated in Figures 6c and d (P o 0.05) .
Engraftment of MUC1-silenced AML cells was associated with an expansion of AML-specific T cells as manifested by a statistically significant increase in BM derived CD4+ cells which expressed IFN-γ upon exposure to autologous tumor lysate (Figure 6e) . Similarly, animals challenged with TIB-49 cells and treated with the MUC1 inhibitor GO-203 daily for 14 days showed a significantly decreased AML involvement (Figure 7a) , decreased PD-L1 expression ( Figure 7b ) and a twofold expansion in AML-specific T cells upon ex vivo exposure to leukemia derived antigens, in the BM of analyzed animals ( Figure 7c ). We subsequently examined the impact of targeting MUC1 on the immunogenicity of human AML cells. MUC1 was silenced in MOLM-14 and THP-1 cells using a lentiviral shRNA and compared to MOLM-14 and THP-1 cells infected with control shRNA. Silencing of MUC1 resulted in enhanced susceptibility to immune-mediated killing by alloreactive lymphocytes as determined by the cleavage of the tumor derived Granzyme B substrate in a standard cytotoxic T lymphocyte (CTL) assay (Figure 8a) . We have developed a leukemia-specific vaccine in which Representative example of allogeneic cytotoxic T lymphocyte assay depicting allogeneic PBMC response against MUC1-silenced and control AML cells (n = 2). (b) Tumor cells were obtained from bone marrow aspirate from patient with AML at diagnosis. Peripheral blood was obtained from the same patient at remission, DC were generated from the PBMCs and fused with the autologous tumor cells. The PBMCs were then stimulated with the fusion cells for 6 days in a 1:5 ratio and then co-cultured with autologous tumor cells that were either pre-treated with 2.5 μM GO-203 for 3 days or control tumor cells. Tumor lysis was detected after the addition of FITC-granzyme B substrate as a percent of APC+FITC+ cells detected by flow cytometric analysis.
patient-derived AML cells are fused with autologous DCs such that a broad array of tumor antigens are presented in the context of DC mediated costimulation. 44 To investigate the capacity of patient-derived T cells to target autologous tumor, PBMCs were stimulated with DC/AML fusion vaccine. Consistent with the immunoregulatory effect of MUC1 and the decrease in PD-L1 levels following exposure to GO-203 in patient-derived AML blasts (Figure 1c ; n = 2), treatment of patient-derived AML cells with the MUC1 inhibitor GO-203, lead to enhanced susceptibility to immune-mediated killing, by DC/AML fusion vaccine stimulated autologous T cells (Figure 8b ).
DISCUSSION
The BM microenvironment in patients with AML is characterized by an immunosuppressive milieu that promotes tumor tolerance, immune escape and disease growth.
1,2 PD-L1 expression by tumor cells is a critical contributor to the immunosuppressive environment. 6 Ligation of PD-1 on T cells in the tumor bed induces an exhausted T-cell phenotype resulting in the loss of activation, expansion and functional capacity of tumor reactive lymphocytes. 45 PD-L1 is strongly expressed by AML cells 3, 5, 6 and is also expressed by other immunosuppressive elements in the BM microenvironment. [46] [47] [48] Defining the mechanisms by which PD-L1 expression is regulated is vital to better understand the evolution of immune dysregulation in AML and as a basis for the design of novel therapies to restore immune function.
The MUC1 oncogene is aberrantly expressed on solid tumors 49 and in hematological malignancies 11, 50 including AML, 25, 51 and supports critical aspects of malignant transformation including resistance to apoptosis, 52 cell proliferation, 26 tissue invasion and metastatic potential. 49 However, its role in immune regulation and tumor-mediated tolerance has not been well defined.
In the present study, we report on the novel finding that the MUC1 oncogene exerts a potent immunomodulatory effect through its regulation of PD-L1 expression on AML cells. Suppression of MUC1 expression via MUC1-specific shRNA or CRISPR-mediated gene deletion, results in the near abrogation of PD-L1 expression. In an immunocompetent murine model, ex vivo silencing of MUC1 in TIB-49 AML cells before tumor challenge, results in durable absence of PD-L1 in the engrafted leukemia cells. Of note, prior studies have shown that PD-L1 expression on AML cells is dynamic, likely regulated by factors in the microenvironment. 6 The present findings suggest that the MUC1 oncogene has a critical role in regulating the immunosuppressive nature of the tumor microenvironment, via its effect on PD-L1. Of note, we have demonstrated that MUC1 expression by tumor cells may be upregulated through interactions between tumor cells and accessory cells in the microenvironment. 53 Interestingly, silencing of MUC1 is paradoxically associated with an increase in PD-L1 mRNA expression, suggesting that MUC1 regulation of PD-L1 is likely mediated by a post-transcriptional mechanism. Noncoding RNAs have been identified as critical mediators of cellular function and may act as effectors of epigenetic regulation in malignant cells. 29, 54, 55 MicroRNAs bind to the 3′-UTR sequence of candidate mRNAs leading to prevention of protein translation. 28 It was previously shown that miR-200c is complementary to the 3′-UTR sequence of PD-L1 mRNA in a lung cancer model. 29 In the present investigation, we demonstrate that that MUC1 negatively regulates miR-34a and miR-200c in AML and that the overexpression of these miRNAs in AML cells results in the near abrogation of PD-L1 expression.
The role of MUC1 in modulating multiple microRNA species raised the possibility of a common processing pathway being targeted by this oncogene. In the present study, we demonstrated that silencing MUC1 is associated with an increase in levels of DICER, an protein critical for mature microRNA formation. 56 The generation of functionally active microRNAs is dependent on carefully scripted sequence of events beginning with the transcription of genomic DNA containing microRNA sequences, that are further processed into precursor-microRNAs (pre-microRNAs) by a nuclear protein complex. [56] [57] [58] Pre-microRNAs are then transported to the cytoplasm, loaded onto a protein complex called the RNA-induced silencing complex composed of Dicer, Argonaute-2 (Ago-2), the Tar RNA-binding protein, and cleaved to their mature form by DICER. 58 Mature microRNAs are then capable of binding to target mRNAs preventing their translation to protein. 28 In the present study, we demonstrate that suppression of MUC1 is associated with increased levels of DICER, consistent with an increase in production of the functionally mature miR-34a and miR-200c. It has been previously shown that the transcription factor, c-Jun, acts as a primary regulator of DICER expression. 37 We have replicated this finding in an AML model, demonstrating direct binding of c-Jun within the DICER promoter using chromatin Immunoprecipitation. Furthermore, in the present study, we demonstrate that silencing or inhibition of MUC1 results in increased levels of phosphorylated c-Jun consistent with an associated increase in DICER expression. Conversely, the introduction of a c-Jun inhibitor reversed the effect of MUC1 silencing on DICER expression in a dose dependent fashion.
To assess the mechanism by which MUC1 regulates c-Jun expression, MUC1-silenced MOLM-14 and THP-1 cells were assessed for ERK and p-ERK expression. We have previously demonstrated that MUC1 signaling regulates ERK expression and activation. 59 Furthermore, ERK was reported to regulate c-Jun expression in multiple cancer models. [39] [40] [41] Interestingly, MUC1 silencing in AML cells resulted in increase in total and phosphorylated ERK expression, suggesting that MUC1 regulation of c-Jun expression occurs, in part, via ERK mediated signaling. Moreover, given the marked increase in phospho c-Jun expression following MUC1 silencing, we sought to examine whether MUC1 signaling also effects c-Jun activation. Indeed, analysis of JNK expression, which has been widely shown to effect c-Jun activation, 42, 43 was demonstrated to be significantly increased following MUC1 silencing in both MOLM-14 and THP-1 cells. These results are consistent with reported JNK regulation by MUC1 signaling. 60 , 61 The results demonstrate that MUC1 signaling effects c-Jun activation as well as expression. This is the first report of an oncogene regulating DICER as a means of governing oncogenic potential. We demonstrate that MUC1 regulation of DICER is associated with a downstream effect on miR-34a and miR-200c and resultant PD-L1 expression. While genetic deletion of DICER is lethal in utero 56 investigators have examined the selective deletion in subsets of cells and have demonstrated that loss of DICER may be associated with loss of function and blunting of differentiation in immune cells. 62 Conflicting data regarding the role of DICER in malignancy has been observed, with some models demonstrating loss of DICER associated with disease progression. 63, 64 Similarly, microRNAs have been shown to mediate diverse effects in tumor models with upregulation of certain microRNA families associated with malignant transformation. 65 However, given the role of microRNAs in disrupting protein translation, the loss of microRNAs due to the oncogenic regulation may result in the increased expression of critical oncoproteins. In the present study, as predicted by its effect on DICER, we demonstrate that MUC1-silencing results in a broad class effect on the generation of functionally active microRNAs. In fact, in MOLM-14 cells, MUC1 silencing was associated with an increase in 98% of microRNA species. Interestingly, MUC1 silencing did not lead to change in cell viability as determined by annexin/PI analysis in MOLM-14 and THP-1 cells. 66 However, tumor cell proliferation was shown to be reduced in MOLM-14 CRISPR cells as determined by Ki67 analysis (Supplementary Figure 2D) .
Consistent with its role in modulating PD-L1 expression, we demonstrate that MUC1 exerts a potent negative immunoregulatory effect in AML. In an immunocompetent AML model, animals engrafted with MUC1-silenced AML cells developed greater evidence of leukemia-specific immunity, compared to control cells, as manifested by increased levels of leukemiaspecific T cells detected in the BM, determined by the percent of cells expressing IFN-γ following exposure to tumor lysate. While the higher levels of engraftment seen in animals receiving control tumor may be associated a greater degree of immune suppression, the emergence of leukemia reactive T cells also likely reflects the greater immunogenicity of AML cells in the setting of MUC1 inhibition. Consistent with this hypothesis, killing of human AML cells by alloreactive lymphocytes is enhanced in MUC1-silenced AML targets. Similarly, exposure to a MUC1 inhibitor renders AML cells more susceptible to lysis by T cells stimulated by leukemia vaccine generated by primary AML cells fused with autologous DCs.
The observation that MUC1 modulation of miR-200c and miR-34a levels regulates PD-L1 expression in AML lends itself to several areas of clinical translation. Blockade of the PD-L1/PD-1 pathway has emerged as a major area of cancer therapeutics with profound and durable responses seen in a subset of patients with advanced melanoma, 67 renal cell carcinoma, 7 and non-small cell lung cancer. 9 The presumptive mechanism of this clinical effect is the breaking of tolerance of tumor reactive lymphocytes and the generation of tumor-specific immunity. A recent report of patients with advanced Hodgkin's disease demonstrates that blockade of this pathway results in durable disease response in 87% of patients.
10 PD-L1 expression by tumor cells is of likely prognostic importance and potentially predictive of response to antibodies that provide checkpoint blockade. Expression is likely to be dynamic, arising out of the interactions with stromal elements in the BM microenvironment. As such, staining characteristics of ex vivo cells may not be reliable and in vivo biomarker that correlates with PD-L1 expression is of potential great clinical significance.
We have developed a MUC1 inhibitor consisting of a cellpenetrating peptide that blocks MUC1 signaling by preventing dimerization necessary for translocation of the MUC1-C component from the plasma membrane to the nucleus. 18 Exposure to the MUC1 inhibitor results in downregulation of PD-L1 expression in primary AML cells and potentially renders them more susceptible to T-cell-mediated recognition and lysis. Investigators have begun to explore the use of microRNAs as therapeutic agents. 68 Strategies to enhance miR-34a or miR-200c expression or by the introduction of microRNA mimetics might similarly result in an enhanced immunologic milieu.
We have developed a tumor vaccine in which patient-derived AML cells are fused with autologous DCs such that a broad array of tumor antigens are presented in the context of DC mediated costimulation. 44, 45 Vaccination with DC/AML fusions results in the expansion of leukemia-specific T cells and protection from relapse. 44 Vaccine efficacy is likely blunted by the presence of PD-L1 expression on the hybridoma cells as well as its presence as a tolerizing influence in the BM microenvironment. In an immune competent AML murine model, combining vaccination with GO-203 treatment, was shown to enhance the vaccine potency (unpublished data). We are currently exploring the use of the MUC1 inhibitor and microRNA mimetics to create an enhanced platform for the development of tumor-specific immunity using a leukemia cancer vaccine.
In summary, we have identified a novel mechanism by which the MUC1 oncoprotein upregulates PD-L1 expression by AML cells through its effect on microRNA species. We have identified a novel mechanism of tumorigenesis through the downregulation of DICER and the loss of microRNA species that regulate proteins with pro-oncogenic function such as PD-L1.
